Trading Update and Notice of Results

Bioventix plc
(“Bioventix” or the “Company”)

Trading update and notice of results

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces a trading update following the year ended 30 June 2015.

As highlighted in the interim results, the core business remains robust and the board is pleased to report that revenues for the year are expected to be in excess of £4.2m (2014:£3.5m).  Given the relatively modest and fixed cost base, profits before tax will be significantly ahead of market expectations.

The Company expects to announce its preliminary results for the year ended 30 June 2015 on 5 October 2015.

For further information please contact:

Bioventix plc Peter Harrison	Chief Executive Officer	Tel: [phone]
finnCap Ltd Geoff Nash/Simon Hicks Steve Norcross	Corporate Finance Corporate Broking	Tel: [phone]

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.